Related Experiment Video
Updated: Apr 12, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
23.5K
Antifibrotic therapies in the liver
1Section of Digestive Diseases, Yale University, New Haven, Connecticut.
Seminars in Liver Disease
|May 15, 2015
Summary
Liver fibrosis is dynamic, with potential for regression through fibrolysis. New antifibrotic therapies show promise, but challenges remain in personalized treatment and combination strategies for liver fibrosis.
Area of Science:
- Hepatology
- Fibrosis Research
- Translational Medicine
Background:
- Liver fibrosis is a dynamic process involving fibrogenesis and fibrolysis.
- Cell populations exhibit plasticity, influencing fibrotic or fibrolytic properties.
- Therapeutic targets for fibrosis progression and regression are increasingly identified.
Purpose of the Study:
- To summarize recent advancements in antifibrotic therapies for liver fibrosis.
- To discuss challenges in understanding interindividual heterogeneity and patient stratification.
- To explore the potential of combination therapy for liver fibrosis treatment.
Main Methods:
- Review of recent progress in antifibrotic therapies.
- Discussion of challenges in noninvasive assessment of fibrogenesis and fibrolysis.
- Analysis of individualized therapy targeting and dose titration.
Main Results:
- Significant progress in understanding liver fibrosis dynamics and therapeutic targets.
- Emerging data on antifibrotic therapies, including FDA-approved agents for pulmonary fibrosis.
- Identification of key challenges in clinical application and patient management.
Conclusions:
- Antifibrotic therapy development is central to translational hepatology.
- Personalized medicine approaches and noninvasive assessment methods are crucial.
- Combination therapy may offer a potent strategy for treating liver fibrosis.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
353
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
353
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:30Inhibitors of Viral Protein Synthesis
35
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
35
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
661
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
661
01:30Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K